: Patients receiving chimeric antigen receptor T cells (CAR-T cells) therapy may be particularly susceptible to coronavirus disease 2019 (COVID-19) because of several factors including the immunosuppression associated to the underlying disease and delayed cytopenias. Regrettably, data on outcomes of CAR-T recipients with COVID-19 are extremely scarce. The aim of this study was to investigate the characteristics and outcomes of COVID-19 in patients treated with CAR-T therapy. The European Hematology Association - Scientific Working Group Infection in Hematology endorsed a survey to collect and analyze data from patients developing COVID-19 after CAR-T therapy. Overall, 459 patients treated with CAR-T cells were reported from 18 European centers. The prevalence of COVID-19 cases was 4.8%. Median time from CAR-T therapy and COVID-19 diagnosis was 169 days. Severe infection occurred in 66.7% of patients and 43.3% of the subjects required admission to ICU. The COVID-19 mortality was 33%. In multivariable analysis, the disease status at the time of COVID-19 trended marginally towards adverse outcome (P=0.075). In conclusion, we documented a high fatality rate for CAR-T patients with COVID-19, supporting the need to design successful interventions to mitigate the risk of infection in this vulnerable group of patients.
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP / A. Busca, J. Salmanton-García, P. Corradini, F. Marchesi, A. Cabirta, R. Di Blasi, R. Dulery, S. Lamure, F. Farina, B. Weinbergerová, J. Batinić, A. Nordlander, A. Lopez-Garcia, L. Drgona, I. Espigado, I. Falces-Romero, R. Garcia-Sanz, C. Garcia-Vidal, A. Guidetti, N. Khanna, A. Kulesekararaj, J. Maertens, M. Hoenigl, N. Klimko, P. Koehler, A. Pagliuca, F. Passamonti, O. Cornely, L. Pagano. - In: BLOOD ADVANCES. - ISSN 2473-9529. - (2021). [Epub ahead of print] [10.1182/bloodadvances.2021005616]
|Titolo:||COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||2021|
|Data ahead of print / Data di stampa:||8-nov-2021|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1182/bloodadvances.2021005616|
|Appare nelle tipologie:||01 - Articolo su periodico|